Apr 8, 2022 · Rasagiline is a selective monoamine oxidase B (MAOB) inhibitor widely used to treat symptoms of Parkinson’s disease. It works by blocking the breakdown of dopamine, thus increasing dopaminergic function in the brain. Rasagiline was approved for marketing in Europe in 2005 and in the United States in 2006.

Dec 30, 2019 · Rasagiline A Parkinson’s disease drug showed some signs of efficacy in people with AD, according to results from a small proof-of-concept study of rasagiline presented by Dawn Matthews of ADM Diagnostics in Northbrook, Illinois. The drug inhibits monoamine oxidase B (MAOB), an enzyme that promotes the breakdown of dopamine and thus boosts ...

Rasagiline has still not been approved by the US Food and Drug Administration for PD, and the current study was undertaken to determine the safety and efficacy of the drug. The Parkinson Study Group conducted a multicenter, 26-week, parallel-group, randomized, double-blind, placebo-controlled study of 404 patients with early PD who were not ...

Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer's Disease. Curr Pharm Des. 2020 Apr 5; PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.

A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease. Mov Disord. 2024 Feb;39(2):350-359. Epub 2023 Oct 27 PubMed. Recommends. Please login to recommend the paper. Comments. No Available ...

Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 May;31(5):709-14. Epub 2016 Mar 31 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.

Rasagiline, sleep quality and well-being in Parkinson's disease: a pilot study. Neurol Sci. 2022 Aug;43(8):4791-4796. Epub 2022 Mar 25 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.

Hattori N, Takeda A, Hanya Y, Kitagawa T, Arai M, Furusawa Y, Mochizuki H, Nagai M, Takahashi R.Effects of rasagiline on Parkinson's Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson's disease: A post-hoc analysis of clinical trials in Japan.

Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline. Mov Disord. 2022 Feb;37(2):325-333. Epub 2021 Nov 1 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.

Safety and effectiveness of rasagiline in patients with Parkinson's disease in Japan: a post-marketing surveillance study. Expert Opin Drug Saf. 2023 Dec 20;:1-10. PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.